Abstract
Cancer therapeutics–related cardiac dysfunction was defined as a decrease in the left ventricular ejection fraction of >10 percentage points, to a value <53%, in a recent expert consensus document ([1][1]). Clinically, early prediction of cardiotoxicity in patients receiving chemotherapy may be
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
